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Tetranectin is a plasminogen kringle 4 domain-binding protein present in plasma and various tissue locations. Decreased plasma
tetranectin or increased tetranectin in stroma of cancers correlates with cancer progression and adverse prognosis. A possible mech-
anism through which tetranectin could inﬂuence cancer progression is by altering activities of plasminogen or the plasminogen
fragment, angiostatin. Tetranectin was found to bind to the kringle 1-4 form of angiostatin (ASTK1-4). In addition, tetranectin in-
hibited binding of plasminogen or ASTK1-4 to extracellular matrix (ECM) deposited by endothelial cells. Finally, tetranectin partially
counteracted the ability of ASTK1-4 to inhibit proliferation of endothelial cells. This latter eﬀect of tetranectin was speciﬁc for ASTK1-4
since it did not counteract the antiproliferative activities of the kringle 1-3 form of angiostatin (ASTK1-3) or endostatin. These ﬁndings
suggest that tetranectin may modulate angiogenesis through interactions with AST.
INTRODUCTION
Tetranectin (TN) plays a role in skeletal formation
during development since targeted deletion of the pro-
tein results in spinal deformity [1]. The function(s) of
t e t r a n e c t i ni np o s t n a t a ll i f eh a v en o tb e e ne l u c i d a t e da l -
thoughthereisevidenceforrolesintissueremodeling,co-
agulation, and cancer. Tetranectin was originally isolated
as a plasminogen-binding protein that can enhance plas-
minogen activation in the presence of tissue plasminogen
activator [2]. Tetranectin binds to plasminogen through
a calcium-sensitive interaction of its C-terminal domain
with kringle 4 domain of plasminogen [3, 4]. Tetranectin
also has a distinct binding site in its N-terminus that
mediates binding to complex sulfated carbohydrates (eg,
heparin) [5]. The N-terminus of tetranectin could, there-
fore,mediatebindingtoextracellularmatrixcomponents.
Plasma levels of tetranectin are approximately 100nM
in healthly adults [6]. However, these levels decline in
patients with cancer and rheumatoid arthritis [6, 7, 8].
Tetranectin is also found in a mobilizable set of gran-
ules in neutrophils [9], in monocytes [10] and platelets
[7], and in various tissue locations like cartilage and the
extracellular matrix (ECM) of developing or regenerat-
ing muscle [11, 12, 13]. Tetranectin is implicated in the
pathogenesis of cancer since decreased plasma levels of
tetranectin correlate with cancer progression [6, 14]. In
the case of ovarian cancer, decreased plasma levels of
tetranectin were a stronger predictor of adverse prognosis
thancancerstage[15].Furthermore,tetranectinispresent
in the stroma of various cancers (eg, breast, ovary, colon),
whereas it is not present in normal tissue from which the
cancers arose [16, 17]. Positive staining for tetranectin in
cancer stroma has also been strongly correlated with can-
cer progression [15].
The mechanisms through which tetranectin may par-
ticipate in cancer progression have not been elucidated.
Tetranectin colocalizes with plasminogen in the invasive
front of melanoma lesions [18], although how tetranectin
aﬀects binding or local activation of plasminogen in can-
cer stroma has not been determined. This paper explores
the hypothesis that tetranectin may interact with angio-
statin. Angiostatin is formed in cancer tissues by pro-
teolytic degradation of plasminogen. The predominant
form of angiostatin produced in cancer tissues is ASTK1-4
[19, 20, 21]. ASTK1-4 inhibits cancer progression and
metastasis by inhibiting cancer-related angiogenesis. We
demonstrate that tetranectin binds to ASTK1-4 and re-
duces its ability to bind to ECM of endothelial cells or to
inhibit endothelial cell growth.
METHODS
Reagents
Humanplasminogenandanantibodydirectedagainst
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Enzyme Research Labs (South Bend, Ind). Rabbit anti-
human tetranectin (with or without horseradish peroxi-
dase attached) was obtained from DAKO Corp (Carpin-
teria, Calif).
Recombinantangiostatinsandendostatin
Recombinant human angiostatins containing kringle
domains 1-3 and 1-4 (ASTK1-3 and ASTK1-4), and recom-
binanthumanendostatinweregraciouslyprovidedbyDrs
Nicolas MacDonald and Kim Lee Sim (EntreMed, Inc,
Rockville,Md).ASTK1-4 wasproducedinChinesehamster
ovary cells and puriﬁed as described in [22]. Endostatin
andASTK1-3 wereproducedinPichiapastoris[23,24].Na-
tive ASTK1-4 derived from human plasma was purchased
from Angiogenesis Research Industries (Chicago, Ill). The
recombinantandnativeangiostatinshadsimilarendothe-
lial cell growth inhibitory properties (data not shown).
Thenativepreparationwasusedintheendothelialgrowth
inhibition assays (see below).
Enzyme-linkedimmunoabsorbentassay(ELISA)
forbindingofangiostatinorplasminogen
totetranectin
Binding of angiostatin or plasminogen to tetranectin
was assessed by coating plates initially with wild type or
mutant forms of tetranectin. Tetranectin was diluted to
a ﬁnal concentration of 6.8µg/mL (100nM) in coating
buﬀer (bicarbonate buﬀer at pH 9.6), added to 96-well
microtitre plates (Costar, Corning Inc, Corning, NY), and
incubated overnight at 4◦C. The wells were washed and
then incubated with either plasminogen (22.5µg/mL) or
angiostatin (50µg/mL) at room temperature for 1 hour.
Bound plasminogen or angiostatin was detected by addi-
tion of a 1 : 1000 dilution of antibody directed against
thekringle1-3domainofplasminogen(EnzymeResearch
Laboratories, South Bend, Ind) for 1 hour at room tem-
perature. Preliminary studies demonstrated that this anti-
body recognized angiostatin and plasminogen to a sim-
ilar extent. A secondary antibody (HRP-labeled donkey
anti-mouse IgG; Jackson Research Labs, West Grove, Pa)
was then added at 1 : 40000 dilution for 1 hour at room
temperature. Binding was detected using a TMB peroxi-
dase EIA substrate kit (BioRad, Hercules, Calif) and 1N
H2SO4. OD 450 readings were measured using a Titertek
Multiscan reader. In all experiments, background binding
of plasminogen and angiostatin was tested by including
additionalwellscoatedwith2.5%BSAonly.Notethatini-
tial experiments were attempted in which angiostatin or
plasminogen was coated onto ELISA plates followed by
addition of tetranectin. However, it was found that back-
ground binding of tetranectin to BSA-coated plates was
too high to reliably assess binding by this method.
Recombinanttetranectins
Recombinant wild-type human tetranectin was pro-
duced in Ec o l i , refolded and puriﬁed as described in [10].
Mutant tetranectins were generated by site-directed mu-
tagenesis as described in [3, 4].
Assayofbindingofplasminogenorangiostatin
toECMofendothelialcells
ECM was prepared from human umbilical vein en-
dothelialcells(HUVECs)grownfor2dayspostconﬂuence
as described in [25]. HUVECs were obtained from Clo-
netics Products, a division of BioWhittaker (San Diego,
Calif) and cultured as outlined in the manufacturer’s in-
structions. The subendothelial matrix was recovered by
removing cells with 0.5% Triton X-100 in PBS (pH 7.4)
followed by incubation with 25mM NH4OH to remove
cytoskeletal elements, and then washed with PBS supple-
mented with 0.05% tween-20. The adherent ECM was
incubated with 1% BSA in PBS to saturate nonspeciﬁc
protein binding sites. AST (at 0.5, 0.25, and 0.125µM)
was preincubated with TN (at 100nM) for 30 minutes at
37◦C and then added to designated wells of 96-well plate.
Bound AST was detected as described above.
Assayofendothelialcellproliferation
HUVECs were seeded overnight in minimum essen-
tial medium containing 2.5% fetal bovine serum (FBS)
in a 96-well plate (5000 cells/well) at 37◦C. The follow-
ing day, fresh medium supplemented with basic ﬁbrob-
last growth factor (bFGF; 10ng/mL) was added. In addi-
tion, tetranectin, angiostatin, or endostatin or combina-
tions of these proteins were added to triplicate wells. The
cells were incubated for 72 hours by replenishing fresh
medium and test substances (bFGF, angiostatin, endo-
statin, tetranectin) as indicated at 24 hours and 48 hours.
Cells were then harvested at 72 hours and counted by
hemocytometer.
RESULTS
Plasminogenandangiostatinbindtotetranectin
As expected, plasminogen bound to recombinant
wild-type tetranectin (Figure 1). Since the form of an-
giostatin composed of kringle domains 1-4 of plasmino-
gen (ASTK1-4) contains the kringle 4, we tested its bind-
ing to tetranectin in parallel. ASTK1-4 also bound sig-
niﬁcantly to tetranectin (Figure 1). The mechanism of
binding of tetranectin to plasminogen has been de-
termined through the use of tetranectin mutants [3].
Binding is calcium-sensitive (ie, reduced by increas-
ing concentrations of calcium) and is mediated by C-
terminal domain of tetranectin. A mutant form of
tetranectin in which lysine 148 was replaced with ala-
nine (TNK148A) binds to plasminogen markedly less than
wild type tetranectin [4]. In contrast, substitution of
threonine 149 with tyrosine (TNT149Y)r e s u l t e di ni n -
creasedbindingtokringle4[4].PlasminogenandASTK1-4
bound signiﬁcantly less to the TNK148A and signiﬁcantly
more to TNT149Y t h a nt ow i l dt y p eT N( Table 1 and
Figure 1).2004:2 (2004) Tetranectin Binds to and Modiﬁes Function of Angiostatin 75
Plasminogen BSA Angiostatin BSA
1.5
1.2
0.9
0.6
0.3
0
M
e
a
n
O
D
4
5
0
Figure 1. Binding of plasminogen or ASTK1-4 to tetranectin.
ELISA plates were coated with recombinant wild-type human
tetranectin (100nM) or BSA, and then treated with plasmino-
gen (22.5µg/mL) and ASTK1-4 (50µg/mL). Results shown are
mean ± SEM of 5 experiments (each experiment done in trip-
licate). Binding of plasminogen and ASTK1-4 to tetranectin was
signiﬁcantlygreaterthanbindingtoBSA-coatedplates(P<. 01).
Binding of plasminogen to TN was signiﬁcantly greater than
binding of ASTK1-4 (P<. 05).
As shown in Figure 1,A S T K1-4 bound to wild-type
TN signiﬁcantly less than plasminogen. However, binding
of ASTK1-4 to the TNT149Y form was equivalent to bind-
ing of plasminogen. Increased plasminogen and angio-
statin binding of TNT149Y could result from the greater
aﬃnity of this mutant for kringle 4. TNT149Y is also dis-
tinguished from wild-type tetranectin in that it binds to
the kringle 2 domain of plasminogen [4], which could
be involved in binding to ASTK1-4. This is likely to be the
case since ASTK1-3 showed signiﬁcant binding to TNY149A,
whereas binding of wild-type TN to ASTK1-3 was not sig-
niﬁcantly greater than background binding to BSA (data
not shown). Nonetheless, binding of ASTK1-3 to TNT149Y
was markedly less than that of ASTK1-4 or plasminogen,
indicating that increased aﬃnity of TNT149Y for kringle 4
accounts for most of the increased binding of this mutant
to ASTK1-4.
Angiostatin(ASTK1-4)bindstoECMof
endothelialcellsandtetranectin
inhibitsthisbinding
Our next goal was to determine if tetranectin alters
functional activities of angiostatin. Plasminogen binds to
ECMofendothelialcells[25,26].Wewantedtodetermine
ifangiostatinalsobindstoECMofendothelialcellsandto
determine the eﬀect of tetranectin on this binding. ECM
of HUVECs was prepared as described in [25]. As shown
in Figure 2, plasminogen did bind to this matrix and this
binding was signiﬁcantly inhibited by pre-incubation of
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Figure 2. Tetranectin reduces binding of plasminogen to ECM
deposited by endothelial cells. ECM of endothelial cells was pro-
duced as described in “methods,” and binding of plasminogen
was measured using ELISA. The eﬀect of tetranectin (wild type)
on binding of plasminogen was assessed by preincubation of
plasminogen with tetranectin (100nM) for 30 minutes at 37◦C,
followed by addition of these samples to wells coated with ECM.
Results shown are mean ± SEM of 4 experiments (each exper-
iment done in triplicate). Binding of plasminogen at 22.5 or
45µg/mL was signiﬁcantly reduced by tetranectin (P<. 05; in-
dicated by ∗).
Table 1. Binding of plasminogen and angiostatin, contain-
ing kringles 1-4 or kringles 1-3 (ASTK1-4,A S T K1-3), to mu-
tant tetranectins. Binding of plasminogen, angiostatin K1-4
(ASTK1-4), or angiostatin K1-3 (ASTK1-3) to TN mutants was as-
sessed by ELISA as in Figure 1. Results shown are mean ± SEM
of 6 speciﬁc binding determinations. Binding of plasminogen or
AST to BSA was subtracted from results shown.
Protein added TNK148A TNT149Y
Plasminogen 0.02 ±0.006 1.73 ±0.14
ASTK1-4 0.06 ±0.02 1.83 ±0.21
ASTK1-3 0.02 ±0.006 0.43 ±0.05
plasminogenwithaphysiologicalconcentration(100nM)
of wild-type tetranectin. As shown in Figure 3,A S T K1-4
also bound to the ECM and binding was again signiﬁ-
cantly reduced by tetranectin.
Tetranectinmodulatestheabilityofangiostatin
toinhibitendothelialcellproliferation
ASTK1-4 signiﬁcantly inhibited the bFGF-stimulated
growth of HUVECs as expected (Figure 4). Tetranectin
alone did not signiﬁcantly alter proliferation in the
presence (Figure 4)o ra b s e n c e( d a t an o ts h o w n )o f
bFGF. However, when HUVECs were treated with both
tetranectin and ASTK1-4, proliferation was signiﬁcantly
greaterthanthatwithASTK1-4 alone.Notethattetranectin
did not completely reverse the antiproliferative action of76 Tirsit Mogues et al 2004:2 (2004)
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Figure 3. Tetranectin reduces binding of angiostatin to ECM.
Bindingofangiostatin(ASTK1-4)toECMofendothelialcellswas
measured as in Figure 2. At all concentrations tested, binding of
ASTK1-4 was signiﬁcantly reduced by tetranectin (P<. 05; indi-
cated by ∗). Results shown are mean ± SEM of 4 experiments
(each experiment done in triplicate).
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Figure 4. Tetranectin counteracts angiostatin-induced inhibi-
tion of proliferation of endothelial cells. HUVECs were seeded
overnight in 96-well plates (5000 cells/well). The following day,
fresh medium supplemented with basic ﬁbroblast growth factor
(bFGF;10ng/mL)wasadded.Whereindicated,tetranectin(TN;
100nM)and/orASTK1-4 (200nM)wereaddedtotriplicatewells.
Cell numbers were counted after 72 hours. ASTK1-4 signiﬁcantly
reduced the number of cells obtained (P<. 008; indicated by ∗).
There were, however, signiﬁcantly more cells in cultures treated
with the combination of tetranectin and ASTK1-4 than in those
treated with ASTK1-4 alone (P<. 039; indicated by #). Note that
culturestreatedwithASTandtetranectinstillhavelesscellsthan
control cultures (P<. 05).
ASTK1-4 since there were still signiﬁcantly fewer cells in
cultures treated with the combination of tetranectin and
ASTK1-4 than in control cultures.
Table 2. Eﬀect of tetranectin on endothelial cell proliferation
in presence of control buﬀer, ASTK1-3 or endostatin. Endothe-
lial cell cultures were incubated for 72 hours in presence of the
indicated concentrations of recombinant wild-type tetranectin,
ASTK1-3, or endostatin alone or combinations of ASTK1-3 or en-
dostatin with tetranectin (ﬁnal concentration 150nM). Results
represent mean±SD number of cells/mL (×1000) in 4–6 exper-
iments (each done in triplicate). All concentrations of ASTK1-3
or endostatin signiﬁcantly decreased endothelial cells numbers
(P<. 05)inpresenceorabsenceoftetranectin.Tetranectinalone
signiﬁcantly (P<. 01) increased the number of endothelial cells
compared with control buﬀer alone although it did not alter the
eﬀects of any concentration of ASTK1-3 or endostatin.
Inhibitor added Control Tetranectin 150nM
Control 43.4 ±1.45 1 ±2.9∗∗
ASTK1-3 10nM 40.5 ±1.93 7 .6 ±5.7
ASTK1-3 50nM 33.2 ±2.23 4 .1 ±4
ASTK1-3 1µM3 2 .3 ±1.62 7 .7 ±1.6
Endostatin 125nM 32.3 ±23 0 .3 ±2
Endostatin 250nM 27.2 ±1.92 3 .1 ±7
Endostatin 500nM 25.1 ±3.52 2 ±3.9
In the experiments shown in Figure 4, there was
a trend (not statistically signiﬁcant) toward increased
proliferationofendothelialcellsinresponsetotetranectin
alone. It was possible, therefore, that the ability of
tetranectin to counteract the antiproliferative activity of
ASTK1-4 resulted from independent eﬀects of tetranectin
on endothelial cell proliferation, rather than from its in-
teractionwithASTK1-4.Tostudythisfurther,wetestedthe
activity of additional concentrations of tetranectin alone,
or tetranectin in combination with endostatin or ASTK1-3
(Table 2). In these experiments, 150nM concentration of
tetranectin alone modestly but signiﬁcantly increased en-
dothelial cell proliferation. However, a further increase of
theconcentrationoftetranectinto375nMresultedinloss
of this enhancing activity (ie, endothelial cell counts in
cultures treated with 375nM tetranectin were 38±3×103
as compared to 43 ± 1.4i nc o n t r o l ;n = 6; P<. 06).
Both endostatin and ASTK1-3 inhibited the growth of en-
dothelial cells as expected (Table 2). However, tetranectin
(150nM) did not lessen the antiproliferative eﬀect of ei-
ther ASTK1-3 or endostatin. These results suggest that the
abilityoftetranectintocounteracttheantiproliferativeac-
tivity of ASTK1-4 is not the result of an independent eﬀect
of tetranectin on the endothelial cells.
DISCUSSION
The important novel ﬁndings of this paper are that
tetranectin binds to ASTK1-4, inhibits binding of plas-
minogen and ASTK1-4 to ECM of endothelial cells, and
partially counteracts the eﬀects of ASTK1-4 on endothelial
cell proliferation. The mechanism of binding of ASTK1-4
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studies using mutant forms of tetranectin with enhanced
or reduced ability to bind plasminogen (Table 1). These
results also indicate that interactions of ASTK1-4 with
tetranectin could be modulated through introduction of
discrete modiﬁcations of tetranectin’s binding site for
plasminogen.
It is of note that although tetranectin bound signif-
icantly to ASTK1-4, binding to ASTK1-4 was signiﬁcantly
less than binding to plasminogen. This ﬁnding was un-
expected since ASTK1-4 contains the principal binding
site for tetranectin (ie, kringle 4). It may be that the
conformation of kringle 4 in ASTK1-4 diﬀers suﬃciently
fromitsconformationinplasminogentoaﬀectbindingof
tetranectin. This binding diﬀerence may be signiﬁcant in
some physiological situations. However, the other results
presented in this paper indicate strongly that binding of
tetranectin to ASTK1-4 is suﬃcient to aﬀect other activities
of ASTK1-4.
WedemonstratethatASTK1-4,likeplasminogen,binds
to the ECM of endothelial cells. This ﬁnding is novel and
of interest since it could relate to localization of angio-
statin in vivo. Of more relevance to the aims of this pa-
per, we also found that tetranectin signiﬁcantly reduced
bindingofASTK1-4 toECMofendothelialcells.Theability
of tetranectin to inhibit binding of ASTK1-4 to ECM sug-
geststhatitcouldpromoteangiogenesisinvivo.Wethere-
fore tested whether tetranectin aﬀects the antiangiogenic
activity of ASTK1-4. Physiological concentrations of wild-
type tetranectin signiﬁcantly counteracted the eﬀect of
ASTK1-4 on endothelial cell proliferation. Tetranectin did
not have a similar interaction with ASTK1-3 or endostatin
(Table 2), indicating that its ability to counteract the an-
tiangiogenic eﬀects of ASTK1-4 is dependent on binding to
the kringle 4 domain and not to some other direct inter-
action with endothelial cells. Tetranectin alone had a vari-
ably enhancing eﬀect on endothelial cell growth at some
concentrations. However, this eﬀect was not dose-related
and is unlikely to account for the ability of tetranectin to
counteract antiproliferative eﬀects of ASTK1-4 based upon
results shown in Table 2.
As noted, extensive data derived from the study of
clinical samples suggests that increased tetranectin in
the stroma of cancer tissues is associated with an ad-
verse prognosis in various cancers. Our ﬁndings suggest
that tetranectin may promote tumor progression by fa-
voring angiogenesis. Cancer-associated angiogenesis has
been quantitated by enumeration of the density of mi-
crovessels in tumor stroma. Increased microvessel density
is associated with adverse prognosis in many cancers [27].
Future studies could address whether increased microves-
sel density is associated with stromal tetranectin reactiv-
ity. The ability of tetranectin to modify other functional
properties of angiostatin should also be examined. One
immediate implication of our ﬁndings is that ASTK1-4 and
ASTK1-3 may have diﬀerent activities in vivo based on dif-
ferential binding to tetranectin. This might account for
the increased elimination half-life of ASTK1-4 compared
with ASTK1-3 in vivo, or the fact that a similar inhibition
of cancer metastases was obtained with lower eﬀective in
vivo exposure to ASTK1-3 than ASTK1-4 [22].
Angiostatinmayinhibitangiogenesisininﬂammatory
states [28] or after vascular injury [29]. Recent studies
demonstrate that biologically active angiostatin is pro-
duced by neutrophils [30], and that angiostatin inhibits
neutrophil migration and inﬂammation-induced angio-
genesis [31]. Of interest, prior studies demonstrated that
t e t r a n e c t i ni sc o n t a i n e di nas u b s e to fn e u t r o p h i l s ,f r o m
which it can be released after cell stimulation with var-
ious agonists [9]. Hence, interactions of tetranectin and
plasminogen or angiostatin may also be involved in in-
ﬂammatory processes. Whereas angiostatin produced in
cancer tissues appears most often to be ASTK1-4 [19, 21],
neutrophils produce ASTK1-3 [30]. Therefore, the partici-
pation of tetranectin in angiogenesis may vary in diﬀerent
physiological or pathological states depending on which
form of angiostatin is produced.
In summary, we demonstrate that tetranectin binds to
theformofangiostatincommonlyproducedincancertis-
sues,characterizethemechanismofbindingusingmutant
forms of tetranectin, and show that tetranectin inhibits
important functional properties of angiostatin. These
ﬁndings provide insight into the mechanisms through
which tetranectin participates in cancer progression. Fur-
thermore,theseﬁndingshaveimplicationsfortherapeutic
use of diﬀerent forms of angiostatin.
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